Quantcast
Home > Quotes > SNDX
SNDX

Syndax Pharmaceuticals, Inc. Common Stock (SNDX) Quote & Summary Data

$4.91
*  
0.03
0.61%
Get SNDX Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading SNDX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
12
Today's High / Low
$ 4.92 / $ 4.78
Share Volume
328,714
50 Day Avg. Daily Volume
308,048
Previous Close
$ 4.88
52 Week High / Low
$ 15.20 / $ 4.36
Market Cap
121,944,519
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.01
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.71

Intraday Chart

Shares Traded

Share Volume:
328,714
50 Day Avg. Daily Volume:
308,048

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.01

Trading Range

The current last sale of $4.91 is 12.61% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.92 $ 15.20
 Low: $ 4.78 $ 4.36

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat is a once-weekly, oral, small molecule, Class I HDAC inhibitor currently being evaluated in a Phase 3 clinical trial in combination with exemestane for advanced hormone receptor positive, or HR+, human epidermal growth factor receptor 2 negative, or HER2-, breast cancer, an indication for which it has been granted Breakthrough Therapy Designation by the FDA. Entinostat has been shown to block the function of immune suppressive cells in the tumor microenvironment, and is being evaluated in combination with several approved PD-1/PD-L1 antagonists, including in ongoing Phase 1b/2 clinical trials combining entinostat with Keytruda┬« from Merck & Co., Inc. for non-small cell lung cancer, melanoma and colorectal cancer; with Tecentriq┬« from Genentech, Inc.  ... More ...  


Risk Grade

Where does SNDX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.82
Open Date:
Dec. 14, 2018
Close Price:
$ 4.91
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info